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Background: In addition to lung involvement, several other diseases and syndromes coexist 
in patients with chronic obstructive pulmonary disease (COPD). Our purpose was to investigate 
the prevalence of idiopathic arterial hypertension (IAH), ischemic heart disease, heart failure, 
peripheral vascular disease (PVD), diabetes, osteoporosis, and anxious depressive syndrome 
in a clinical setting of COPD outpatients whose phenotypes (predominant airway disease and 
predominant emphysema) and severity (mild and severe diseases) were determined by clinical 
and functional parameters.
Methods: A total of 412 outpatients with COPD were assigned either a predominant airway 
disease or a predominant emphysema phenotype of mild or severe degree according to predic-
tive models based on pulmonary functions (forced expiratory volume in 1 second/vital capacity; 
total lung capacity %; functional residual capacity %; and diffusing capacity of lung for carbon 
monoxide %) and sputum characteristics. Comorbidities were assessed by objective medical 
records.
Results: Eighty-four percent of patients suffered from at least one comorbidity and 75% from 
at least one cardiovascular comorbidity, with IAH and PVD being the most prevalent ones 
(62% and 28%, respectively). IAH prevailed significantly in predominant airway disease, 
osteoporosis prevailed significantly in predominant emphysema, and ischemic heart disease 
and PVD prevailed in mild COPD. All cardiovascular comorbidities prevailed significantly in 
predominant airway phenotype of COPD and mild COPD severity.
Conclusion: Specific comorbidities prevail in different phenotypes of COPD; this fact may be 
relevant to identify patients at risk for specific, phenotype-related comorbidities. The highest 
prevalence of comorbidities in patients with mild disease indicates that these patients should be 
investigated for coexisting diseases or syndromes even in the less severe, pauci-symptomatic 
stages of COPD. The simple method employed to phenotype and score COPD allows these 
results to be translated easily into daily clinical practice.
Keywords: COPD phenotypes, COPD severity, comorbidities
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition diagnosed 
by not completely reversible airflow obstruction detected during spirometry. Beyond 
this unifying functional definition, it is known that the lung may react to cigarettes 
smoking and environmental exposure with conductive airways remodeling or paren-
chymal destruction. The prevalence of airways or parenchymal changes determines 
the prevalent phenotype of COPD. The extent and the concomitance of airways and 
parenchymal changes determine the severity of the disease. In the last few years, several 
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methods to identify the predominant phenotype and the sever-
ity of COPD in clinical practice have been proposed.1–5
In addition to lung involvement, several “comorbidities” 
may coexist in patients with COPD such as cardiovascular 
disease, metabolic dysfunctions, and anxious–depressive 
disorders as the most commonly reported. A number of poten-
tial biological mechanisms linking COPD and comorbidities 
have been proposed: the proinflammatory milieu,6–8 increased 
oxidative stress,9 increased arterial stiffness,10,11 catabolic 
state,12 and sedentary lifestyle.13 As a matter of fact, patients 
with COPD are often “multi-diseased patients,” presenting 
different clinical pictures, with a poorer quality of life and 
outcomes,14 and a high disease-related burden.15,16 They also 
need a complex diagnostic and therapeutic approach.17
The prevalence of the various comorbidities in COPD 
varies widely according to the methods used to define phe-
notype and severity of the disease.18–22 The purpose of this 
study is to investigate the prevalence of idiopathic arterial 
hypertension (IAH), ischemic heart disease (IHD), heart 
failure (HF), peripheral vascular disease (PVD), diabetes (D), 
osteoporosis (O), and anxious depressive syndrome (ADS) 
in a clinical setting of COPD outpatients whose predominant 
phenotype and severity were determined by a standardized 
method, derived from computerized tomography (CT),2 
allowing patients to be classified based on simple clinical 
and pulmonary function parameters.
Materials and methods
Patients
A total of 412 outpatients with COPD (299 males), in stable 
clinical condition were consecutively enrolled and completed 
the study. The ethical committee of the University Hospital 
of Florence approved the study and an informed consent was 
signed by each patient.
Patients’ evaluation consisted of a thorough clinical 
history and physical examination. Severity of dyspnea was 
assessed by the modified Medical Research Council (mMRC) 
dyspnea scale. Static and dynamic lung volumes and single 
breath diffusing capacity (DL
CO
) were measured (V6200 
Autobox Body Plethysmograph; Sensor Medics, Yorba Linda, 
CA, USA) according to American Thoracic Society/European 
Respiratory Society guidelines and expressed as percentage 
of the predicted values (%).23
 
Each patient was assigned a 
predominant airway or predominant emphysematous pheno-
type and a mild or severe category of disease according to the 
results of a multivariate analysis of 14 continuous variables 
(age, years; body mass index [BMI]; pack/years; forced 
vital capacity [FVC]% predicted; forced expiratory volume 
in 1 second [FEV
1
] % predicted; FEV
1
/vital capacity [VC] 
and FEV
1
/FVC ratios, total lung capacity [TLC] % predicted, 
residual volume [RV] % predicted, RV/TLC ratio, func-
tional residual capacity [FRC] % predicted; VC% predicted; 
inspiratory capacity [IC] % predicted; DL
CO
 % predicted plus 
three categorical variables (mMRC dyspnea scale, cough, and 
sputum, scored as follows: dyspnea [0= none; 1= slight; 2= 
moderate; 3= severe; 4= very severe]; cough [0= absent; 1= 
occasional; 2= chronic]; and sputum [0= absent/occasional; 
1= chronic non-purulent; 2= chronic purulent]), which have 
been validated by quantitative CT.2 The variables entered 
to classify COPD patients according to the predominant 
mechanism of airflow limitation were DL
CO
%, TLC%, and 
sputum purulence. These variables were linearly combined 
to determine the relative predominance of an airway or 
emphysema phenotype according to the following computa-
tion. Sputum purulence was assigned a categorical value (0, 
absent; 1, present).
 
Phenotype 0.324 0.018 DL % 0.58
(sputum purulence) 0.011
CO
= − × −
× + ×TLC%
Patients were classified as being affected by predominant 
emphysema or by predominant airway disease when the 
result of the above-mentioned equation was either positive 
or negative, respectively.2
FEV
1
/VC ratio, FRC%, and sputum purulence were 
entered to classify the severity of the disease. These variables 
were linearly combined to compute the COPD severity score 
according to the following equation:
 
Severity 0.575 0.013 FEV /VC 0.013
(sputum purulence) 0.0
1
= −− × +
× + 13 FRC%×
Patients were classified as being affected by severe or 
mild disease when the result of the computation was positive 
or negative, respectively.2
Comorbidities
The following comorbidities were chosen to investigate car-
diovascular, metabolic, and behavioral domains in patients 
with COPD. We ascertained the presence of IAH, IHD, HF, 
PVD, D, O, and ADS by means of an interview, outcomes 
of functional diagnostic procedures, and current medical 
treatment. The presence of each comorbidity was confirmed 
by the investigators through a detailed review of available 
medical records and medications or therapy specific to any 
disease. Self-reported diagnoses were not considered.
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statistical analysis
Data were presented as mean ± standard deviation for 
continuous variables, and as counts and proportions for 
nominal and ordinal variables. The Student’s t-test was 
used to compare the mean of continuous variables among 
different subsets of patients. The Fisher’s exact test was 
used to compare the prevalence of categorical variables 
among different subsets of patients. The significance level 
was set at P,0.05.
Results
Anthropometric, smoke exposure, and functional data of 
the recruited patients and classification according to the 
prevailing phenotype and severity of the disease are reported 
in Table 1. Mild and severe COPD patients were matched 
for age. No difference in smoke exposure was found across 
the subgroups. Compared with patients with predominant 
airway disease, those with predominant emphysema were 
younger, with a lower BMI and a more impaired lung 
function involving all the considered functional variables. 
Table 2 shows the number of comorbidities in the whole set 
and according to prevailing phenotype and disease severity. 
No comorbidities were found in 16% of patients (65 out of 
412). In more details, 29 (13%) predominant airway disease 
patients and 36 (19%) predominant emphysema patients 
had no detectable comorbidities. The number of patients 
with no comorbidities was similar in both the subgroups. 
The vast majority of patients turned out to be affected by 
two or three comorbidities (Table 2). Figure 1 reports the 
overall prevalence of each comorbidity. Figures 2 and 3 
display the prevalence of each comorbidity within each of 
the two phenotypes. Out of 422 patients, 347 (84%) had at 
least one comorbidity. The most frequent was IAH, which 
affected 62% of the patients, followed by PVD (28%). 
Figure 3 shows the prevalence of comorbidities in the two 
phenotypes. While IAH was significantly more prevalent 
Table 1 anthropometric and functional data in patients with COPD according to phenotypes and severity of the disease
COPD 
(n=412)
Predominant 
airway disease 
(n=222)
Predominant 
emphysema 
(n=190)
P-value Mild COPD 
(n=284)
Severe COPD 
(n=128)
P-value
Males/females 299/113 174/48 125/65 195/89 104/24
age 70±9 71±8 69±9 #0.05 70±9 69±8 ns
p/y 46±27 45±29 48±25 ns 45±28 50±24 ns
BMI 26±5 28±5 25±4 #0.0001 27±5 25±4 #0.0001
FeV1 (%) 69±25 76±23 61±26 #0.0001 79±22 48±19 #0.0001
FeV1/VC (%) 52±14 57±11 46±14 #0.0001 58±11 39±12 #0.0001
FrC (%) 120±31 110±25 132±32 #0.0001 107±21 150±29 #0.0001
TlC (%) 105±17 100±16 110±16 #0.0001 100±15 116±15 #0.0001
DlCO (%) 76±23 89±16 61±16 #0.0001 81±21 66±22 #0.0001
Note: Data are presented as mean ± sD.
Abbreviations: BMI, body mass index (weight/height2); COPD, chronic obstructive pulmonary disease; DlCO%, diffusing capacity of lung for carbon monoxide (% of 
predicted); FeV1%, forced expiratory volume in 1 second (% of predicted); FeV1/VC%, FeV1–vital capacity ratio; FrC%, functional residual capacity (% of predicted); ns, 
nonsignificant; p/y, number of daily cigarettes × number of years/20; sD, standard deviation; TlC%, total lung capacity (% of predicted).
Table 2 number of comorbidities in patients with COPD according to phenotypes and severity of the disease
Number of 
comorbidities*
Predominant 
airway disease 
(n=222)
Predominant 
emphysema 
(n=190)
χ2
P-value
Mild disease 
(n=284)
Severe disease 
(n=128)
χ2
P-value
0 29 (13%) 36 (19%) 39 (13%) 26 (20%)
1 72 (32.4%) 67 (35.3%) 96 (34%) 43 (34%)
2 74 (33.3%) 52 (27.4%) 88 (31%) 38 (29.7%)
3 32 (14.4%) 22 (11.6%) 40 (14%) 14 (11%)
4 11 (5%) 9 (4.7%) 16 (6%) 4 (3%)
5 2 (1%) 3 (1.6%) 2 (0.7%) 3 (2.3%)
6 2 (1%) 1 (0.5%) 3 (1%) 0
0–2 175 155 0.53
ns
223 107 0.28
ns3–6 47 35 61 21
Notes: *no patient has more than six comorbidities. The Fisher’s exact test was used to compare the prevalence of comorbidities in the different subsets of patients. 
Significance was set at P,0.05.
Abbreviations: COPD, chronic obstructive pulmonary disease; ns, nonsignificant.
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in patients with predominant airway disease, osteoporosis 
prevailed in those with predominant emphysema. As for 
COPD severity (Figure 4), we found a significantly higher 
prevalence of IHD and PVD in patients with mild COPD. 
Out of 412 patients, 309 (75%) were affected by at least one 
cardiovascular comorbidity. The prevalence of all considered 
cardiovascular comorbidities was significantly higher in 
patients with mild disease and in those with predominant 
airway phenotype of COPD (Figure 5).
Discussion
The main finding of this study was that specific comorbidi-
ties prevailed in the two considered phenotypes of COPD; 
notably the highest prevalence of comorbidities was found 
among patients with mild stage of the disease. In particu-
lar, IAH was significantly more prevalent in patients with 
the predominant airway phenotype, whereas osteoporosis 
seemed to prevail in the predominant emphysema phenotype. 
In addition, we found a significantly higher prevalence of 
IHD and PVD in the subset of patients with mild COPD. The 
second relevant result was that the cardiovascular comorbidi-
ties were found to be significantly more prevalent in patients 
with the predominant airways phenotype and with a milder 
expression of the disease.
A growing body of evidence suggests that COPD is 
associated with comorbidities whose prevalence varies 
largely among epidemiological studies. In this study, the 
prevalence of the whole set of considered comorbidity and 
cardiovascular comorbidities was consistent with those of 
Anecchino et al,18 which was based upon a different method 
for comorbidity detection and classification. Indeed, they 
found at least one prescription of drugs for a chronic condi-
tion other than respiratory disease in a vast majority of their 
wide cohort of patients with COPD. It is important to under-
line that the presence of comorbidities in our study has been 
investigated by an objective method, with the exclusion of 
patients with a single drug prescription and/or a self-reported 
diagnosis, which was not considered probative for the pres-
ence of a comorbidity.
In our study, patients with predominant airway disease 
were slightly older than those with predominant emphy-
sema. This result is in contrast with those of Feary et al20 
and Sode et al19 who showed the highest risk of comorbidity 
in the youngest patients with COPD, suggesting to look 
for comorbidities at earlier stages of the disease. On the 
other hand, the present results of a higher prevalence 
of comorbidities in mild diseases’ severity confirm the 
hypothesis of individual susceptibility to factors implicated 
in the genesis of COPD, which could arise and develop 
up to different degrees of severity, and progress more or 
less into more severe stages independently of the age of 
the patients.
??
??
??
??
???
????
????
????
?????
???
?
?????
? ??? ??? ?? ??? ???? ?
Figure 1 Prevalence of comorbidities in 412 outpatients with COPD.
Abbreviations: aDs, anxious depressive syndrome; com, comorbidities; COPD, 
chronic obstructive pulmonary disease; D, diabetes; hF, heart failure; Iah, idiopathic 
arterial hypertension; IhD, ischemic heart disease; O, osteoporosis; PVD, peripheral 
vascular disease.
??? ?
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Figure 2 Prevalence of comorbidities in 222 patients with the predominant airway disease (A) phenotype and in 190 patients with the predominant emphysema phenotype (B).
Abbreviations: aDs, anxious depressive syndrome; com, comorbidities; D, diabetes; hF, heart failure; Iah, idiopathic arterial hypertension; IhD, ischemic heart disease; 
O, osteoporosis; PVD, peripheral vascular disease.
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In patients with predominant airway phenotype of COPD, 
we observed that the most prevailing comorbidity was IAH. 
This result is consistent with that of Watz et al,24 who detected 
IAH in a high proportion (73%) of patients with symptoms 
of chronic bronchitis without airflow limitation, as well as in 
those with mild COPD (77%). Interestingly, they found that 
circulatory markers of systemic inflammation were increased 
in patients with chronic bronchitis and COPD when metabolic 
syndrome was detected, irrespective of the degree of lung 
function impairment. Visceral adipocytes have been sus-
pected to play a role by producing interleukin-6, which in turn 
induces the synthesis of C-reactive protein by hepatocytes. 
This finding has been confirmed in a study by Poulain et al,25 
who demonstrated that systemic inflammation was higher in 
obese patients with moderate COPD compared with those 
with normal weight and severe disease. We confirmed these 
observations indirectly, as BMI was significantly higher in 
patients with the predominant airway phenotype compared 
with those with predominant emphysema phenotype, and in 
moderate disease compared with severe disease.
Recently, new evidence has emerged suggesting that 
hypoxia, a frequent finding in patients with COPD, may be 
an additional cardiovascular risk factor for its role in the 
atherosclerosis process.26–29 Moreover, patients with COPD 
are often affected by a neglected condition such as sleep 
disorders, resulting in nighttime hypoxia. Obesity strongly 
contributes along with age and active smoking for sleep 
disordered breathing, accelerated pulmonary hypertension, 
obesity–hypoventilation syndrome, and obstructive sleep 
apnea, irrespective of the degree of airflow obstruction.29
Hypoxia resulting from the above-mentioned conditions 
can be continuous or intermittent.26 These high fre-
quency cycles of hypoxia and reoxygenation are similar 
to ischemia–reperfusion injury and result in an increased 
production of reactive oxygen species and oxidative stress. 
Cell damage, remodeling of extracellular matrix and blood 
vessels, endothelial dysfunction, and inactivation of antipro-
teases are some of the consequences of oxidative imbalance. 
Furthermore, in animals models, chronic intermittent hypoxia 
increases the amount of oxidized lipids and low-density 
lipoproteins in serum and arterial walls, which have stronger 
atherogenic effects, such as the formation of plaques in arter-
ies which start due to lipid peroxidation. These results have 
been confirmed and extended in a small cohort of patients 
with COPD and sustained nocturnal, nonapneic hypoxia, 
??
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???????????????????????????????????????????????
Figure 3 Comparisons of the prevalence of each examined comorbidity in 
222 patients with a predominant airway disease phenotype and in 190 patients with 
a predominant emphysema phenotype.
Note: *P,0.05.
Abbreviations: aDs, anxious depressive syndrome; com, comorbidities; D, 
diabetes; hF, heart failure; Iah, idiopathic arterial hypertension; IhD, ischemic heart 
disease; O, osteoporosis; PVD, peripheral vascular disease.
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Figure 4 Prevalence of comorbidities in 412 outpatients according to mild or 
severe grade of COPD.
Notes: *P,0.05; ***P,0.0001.
Abbreviations: aDs, anxious depressive syndrome; com, comorbidities; COPD, 
chronic obstructive pulmonary disease; D, diabetes; hF, heart failure; Iah, idiopathic 
arterial hypertension; IhD, ischemic heart disease; O, osteoporosis; PVD, peripheral 
vascular disease.
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Figure 5 Prevalence of cardiovascular comorbidities in 412 outpatients according 
to mild or severe grade of COPD and according to the predominant phenotype.
Notes: *P,0.05; ***P,0.0001.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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which showed increased levels of serum lipid peroxidation 
and decreased paraoxonase activity.28
Patients with COPD and obesity, hypoventilation syn-
drome, and obstructive sleep apnea resemble the so-called 
“blue bloater” phenotype29 and also the predominant airway 
phenotype objectively classified in this paper.
Among the extrapulmonary effects of COPD, osteo-
porosis has been recognized as a major comorbidity. This 
association has been explained in terms of age, sex, reduced 
daily activity, chronic hypoxemia, and systemic corticoster-
oids therapy.30 Recently, the presence of osteoporosis also 
in patients with milder airflow obstruction and clinically 
stable conditions has led to linking osteoporosis to a low-
grade systemic inflammation sustained by increased plasma 
levels of C-reactive protein, interleukin-6, and tumor necrosis 
factor-α.31 Furthermore, COPD exacerbations, associated 
with increased systemic inflammation, have been demon-
strated to enhance osteoporosis progression.32 The high 
prevalence of osteoporosis in the predominant emphysema 
phenotype in our study supports the view that, beyond a pure 
catabolic process, a mechanical derangement of lung structure 
due to hyperinflation and parenchymal disruption might also 
be relevant in sustaining a widespread chronic inflammation 
and its consequences. It could not be otherwise explained that 
a significant improvement of bone mineral density occurred 
1 year after lung volume reduction surgery in patients with a 
pure, severe, CT-detected emphysema phenotype of COPD 
compared with a control group undergoing rehabilitation.33
The other important finding of this study was that IHD and 
PVD are significantly more prevalent in the subset of patients 
with mild COPD. This finding is in keeping with the previ-
ous studies19,20 demonstrating that the association between 
cardiovascular comorbidities and COPD is a risk factor for 
poor prognosis, hospitalization, and death of patients with 
mild COPD.19 Our results showed that the highest burden 
of comorbidities is seen mostly in patients with less severe 
pulmonary disease. These findings were in agreement with 
findings of Watz et al24 and in contrast with those of Mahboub 
et al22 and Dal Negro et al21 who reported an association 
between the prevalence of comorbidity and COPD severity 
measured by a COPD assessment test score .10 or by Global 
Initiative on Obstructive Lung Disease stages, respectively. 
Our results were also in contrast with Mannino et al34 and 
Johnston et al35 who reported a direct relationship between 
severity of airflow limitation and risk for cardiovascular 
diseases, and for IHD, arrhythmias, stroke, and IAH, each 
one considered separately. Furthermore, other studies failed 
to demonstrate any significant association between the 
prevalence of cardiovascular comorbidities and the severity 
of COPD evaluated by the level of airflow obstruction in a 
small cohort of patients,36 or by the degree of airflow obstruc-
tion, exercise capacity, and BODE index.37
The discrepancies may be related to the method by which 
the disease severity was scored. Conceivably, disease severity 
is unlikely to be satisfactorily depicted by the reduction of a 
single functional parameter (eg, FEV
1
). Indeed, this has been 
the sole criterion employed to assess COPD severity in many 
studies, actually before the publication of the revised Global 
Initiative on Obstructive Lung Disease guidelines in 2011; 
here symptoms and clinical events (exacerbations) have been 
introduced first, along with airway obstruction, to describe a 
disease that is actually far more complex than airway obstruc-
tion alone. Furthermore, this functional feature also reflects 
at least two pathological mechanisms, namely reduction of 
airway caliber (due to inflammation) and reduction of elastic 
recoil (due to parenchymal destruction). We are confident 
that the method employed to investigate COPD in this study 
takes into account both the predominant mechanism of airway 
obstruction for phenotyping each patient and the total amount 
of parenchymal and airways involvement to score severity.2
We acknowledge that this study has some limitations: 
1) the small cohort of patients recruited; 2) the retrospec-
tive collection of data concerning diagnosis and therapy of 
each examined comorbidity; and 3) the methodology used to 
report the presence of a comorbidity that is not completely 
objective because it was not based on repeating or seeking 
confirmatory tests for each disease, a task that would have 
been prohibitively expensive.14,16 Therefore, based on this 
consideration and in keeping with most of the studies on the 
subject, we preferred to assess the presence of a comorbidity 
by means of a combination of clinical history and medical 
records documentation.
Conclusion
Understanding the association between comorbidities and 
phenotypes of COPD may be relevant to clarify the relation-
ship between different pathophysiological mechanisms and 
such a disease: we can hypothesize to assign each phenotype 
of COPD a specific comorbidity panel.
The increased prevalence of comorbidities among 
patients with mild disease has several relevant practical 
aspects: first of all, the need of an early diagnosis of COPD, 
especially in those patients with slight symptoms who turn 
to general practitioners more often than to pulmonologists. 
For this purpose, we wish to stress that the results of this 
study can easily be translated into daily clinical practice due 
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Comorbidities according to phenotypes and severity of COPD
to the simple method suggested here to phenotype and score 
the disease. Accordingly, the complementary role of general 
practitioners and the specialist is highlighted in this study: 
given the large number of potential candidates to develop 
COPD, it would be impossible to care for all patients at a 
specialist level. A need exists to lay bridges and to share a 
common language that allow both specialists and general 
practitioners to diagnose and treat COPD and its comor-
bidities early and effectively, in order to slow the disease 
progression and improve the quality of life.38,39
Increasing knowledge on links between COPD and 
comorbidities could provide innovative treatment strategies 
and it would assign each patient with COPD targeted thera-
pies according to their personalized profile of phenotype, 
severity, and comorbidity.40
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